SCA
PACB icon

Snowden Capital Advisors’s Pacific Biosciences PACB Stock Holding History

Snowden Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,116
Closed -$243K – 1132
2023
Q3 		$243K Sell
29,116
-2,537
-8% -$29K 0.01% 933
2023
Q2 		$421K Buy
31,653
+12
+0% +$146 0.02% 812
2023
Q1 		$366K Sell
31,641
-30,910
-49% -$307K 0.01% 862
2022
Q4 		$512K Sell
62,551
-120
-0.2% -$1.03K 0.02% 699
2022
Q3 		$363K Sell
62,671
-9,902
-14% -$56.8K 0.02% 803
2022
Q2 		$320K Sell
72,573
-4,096
-5% -$24.9K 0.01% 831
2022
Q1 		$697K Buy
76,669
+12,867
+20% +$148K 0.03% 532
2021
Q4 		$1.3M Sell
63,802
-108,816
-63% -$2.63M 0.07% 295
2021
Q3 		$4.41M Buy
172,618
+2,314
+1% +$68.6K 0.22% 136
2021
Q2 		$5.96M Buy
170,304
+609
+0.4% +$17.7K 0.3% 83
2021
Q1 		$5.65M Buy
169,695
+32,087
+23% +$1.12M 0.32% 75
2020
Q4 		$3.57M Buy
137,608
+14,159
+11% +$241K 0.24% 133
2020
Q3 		$1.22M Buy
+123,449
New +$711K 0.1% 245

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Snowden Capital Advisors's PACB Position: Q4 2023 in Review

Snowden Capital Advisors sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 29,116 shares — an estimated $243K sold.

Snowden Capital Advisors first reported a position in PACB in Q3 2020 and held it in 13 quarters. The position peaked at $5.96M in Q2 2021. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Snowden Capital Advisors reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Snowden Capital Advisors sold 29,116 Pacific Biosciences shares in Q4 2023, an estimated $243K.
  • Snowden Capital Advisors first reported a position in Pacific Biosciences in Q3 2020 and held it in 13 quarters.
  • Snowden Capital Advisors's Pacific Biosciences position peaked at $5.96M in Q2 2021.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Snowden Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.